47 results on '"Olesinska, Marzena"'
Search Results
2. Factors associated with quality of life in systemic sclerosis : a cross-sectional study
- Author
-
Sierakowska, Matylda, Doroszkiewicz, Halina, Sierakowska, Justyna, Olesińska, Marzena, Grabowska-Jodkowska, Agnieszka, Brzosko, Marek, Leszczyński, Piotr, Pawlak-Bus, Katarzyna, Batko, Bogdan, Wiland, Piotr, Majdan, Maria, Bykowska-Sochacka, Małgorzata, Romanowski, Wojciech, Zon-Giebel, Aleksandra, Jeka, Sławomir, and Ndosi, Mwidimi
- Published
- 2019
3. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
- Author
-
Lucero, Eleonora, Pons-Estel, Bernardo, Rivero, Mariano, Tate, Guillermo, Smith, Vanessa, De Langhe, Ellen, Rashkov, Rasho, Batalov, Anastas, Goranov, Ivan, Stoilov, Rumen, Dunne, James, Johnson, Sindhu R., Pope, Janet E., Martinović Kaliterna, Dušanka, Mogensen, Mette, Olesen, Anne Braae, Allanore, Yannick, Henes, Joerg Christoph, Müller-Ladner, Ulf, Riemekasten, Gabriela, Skapenko, Alla, Vlachoyiannopoulos, Panayiotis, Kiss, Emese, Minier, Tünde, Beretta, Lorenzo, Gremese, Elisa, Matucci-Cerinic, Marco, Valentini, Gabriele, Asano, Yoshihide, Atsumi, Tatsuya, Ihn, Hironobu, Ishii, Tomonori, Ishikawa, Osamu, Kuwana, Masataka, Shima, Yoshihito, Takahashi, Hiroki, Takehara, Kazuhiko, Tanaka, Yoshiya, Yamasaki, Yoshioki, Bukauskiene, Loreta, Butrimiene, Irena, Medrano Ramirez, Gabriel, Ramos-Remus, Cesar, Sofia Rodriguez Reyna, Tatiana, de Vries-Bouwstra, Jeska, van Laar, Jacob M., Batko, Bogdan, Jeka, Slawomir, Kucharz, Eugeniusz, Majdan, Maria, Olesinska, Marzena, Smolenska, Zaneta, Alves, Jose, Santos, Maria, Mihai, Carmen Marina, Rednic, Simona, Castellvi Barranco, Ivan, Lopez Longo, Francisco Javier, Simeon Aznar, Carmen, Carreira, Patricia, Distler, Oliver, Walker, Ulrich A., Derrett-Smith, Emma, Griffiths, Bridget, McKay, Neil, Denton, Christopher P., Aelion, Jacob, Borofsky, Michael, Fleischmann, Roy, Forstot, Joseph Z., Furst, Daniel E., Kafaja, Suzanne, Khan, M. Faisal, Khanna, Dinesh, Kohen, Michael D., Martin, Richard W., Mendoza-Ballesteros, Fabian, Nami, Alireza, Pang, Shirley, Rios, Grissel, Simms, Robert, Sullivan, Keith Michael, Steen, Virginia D., Lin, Celia J F, Furst, Daniel E, Goldin, Jonathan, Kim, Grace, van Laar, Jacob M, Spotswood, Helen, Wagner, Bridget, Siegel, Jeffrey, Jahreis, Angelika, and Denton, Christopher P
- Published
- 2020
- Full Text
- View/download PDF
4. HIF-1A gene polymorphisms and its protein level in patients with rheumatoid arthritis: a case–control study
- Author
-
Paradowska-Gorycka, Agnieszka, Stypinska, Barbara, Pawlik, Andrzej, Haladyj, Ewa, Romanowska-Próchnicka, Katarzyna, and Olesinska, Marzena
- Published
- 2018
- Full Text
- View/download PDF
5. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products
- Author
-
Talarico, Rosaria, primary, Ramirez, Giuseppe Alvise, additional, Barreira, Sofia C., additional, Cardamone, Chiara, additional, Triggianese, Paola, additional, Aguilera, Silvia, additional, Andersen, Jeanette, additional, Avcin, Tadej, additional, Benistan, Karelle, additional, Bertsias, George, additional, Bortoluzzi, Alessandra, additional, Bouillot, Coralie, additional, Bulina, Inita, additional, Burmester, Gerd R., additional, Callens, Steven, additional, Carreira, Patricia E., additional, Cervera, Ricard, additional, Cutolo, Maurizio, additional, Damian, Laura, additional, Della-Torre, Emanuel, additional, Faria, Raquel, additional, Fonseca, João E., additional, Galetti, Ilaria, additional, Hachulla, Eric, additional, Iaccarino, Luca, additional, Jacobsen, Søren, additional, Khmelinskii, Nikita, additional, Limper, Maarten, additional, Marinello, Diana, additional, Meyer, Alain, additional, Moroncini, Gianluca, additional, Nagy, Gyorgy, additional, Olesinska, Marzena, additional, Pamfil, Cristina, additional, Pileckyte, Margarita, additional, Pistello, Mauro, additional, Rednic, Simona, additional, Richez, Christophe, additional, Romão, Vasco C., additional, Schneider, Matthias, additional, Sciascia, Savino, additional, Scirè, Carlo Alberto, additional, Simonini, Gabriele, additional, Smith, Vanessa, additional, Sulli, Alberto, additional, Tani, Chiara, additional, Tas, Sander W., additional, Tincani, Angela, additional, Vonk, Madelon C., additional, Tektonidou, Maria, additional, and Mosca, Marta, additional
- Published
- 2023
- Full Text
- View/download PDF
6. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups
- Author
-
Lundberg, Ingrid E, Tjärnlund, Anna, Bottai, Matteo, Werth, Victoria P, Pilkington, Clarissa, Visser, Marianne de, Alfredsson, Lars, Amato, Anthony A, Barohn, Richard J, Liang, Matthew H, Singh, Jasvinder A, Aggarwal, Rohit, Arnardottir, Snjolaug, Chinoy, Hector, Cooper, Robert G, Dankó, Katalin, Dimachkie, Mazen M, Feldman, Brian M, Torre, Ignacio Garcia-De La, Gordon, Patrick, Hayashi, Taichi, Katz, James D, Kohsaka, Hitoshi, Lachenbruch, Peter A, Lang, Bianca A, Li, Yuhui, Oddis, Chester V, Olesinska, Marzena, Reed, Ann M, Rutkowska-Sak, Lidia, Sanner, Helga, Selva-O’Callaghan, Albert, Song, Yeong-Wook, Vencovsky, Jiri, Ytterberg, Steven R, Miller, Frederick W, and Rider, Lisa G
- Published
- 2017
- Full Text
- View/download PDF
7. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
- Author
-
van Vollenhoven, Ronald, Voskuyl, Alexandre, Bertsias, George, Aranow, Cynthia, Aringer, Martin, Arnaud, Laurent, Askanase, Anca, Balážová, Petra, Bonfa, Eloisa, Bootsma, Hendrika, Boumpas, Dimitrios, Bruce, Ian, Cervera, Ricard, Clarke, Ann, Coney, Cindy, Costedoat-Chalumeau, Nathalie, Czirják, László, Derksen, Ronald, Doria, Andrea, Dörner, Thomas, Fischer-Betz, Rebecca, Fritsch-Stork, Ruth, Gordon, Caroline, Graninger, Winfried, Györi, Noémi, Houssiau, Frédéric, Isenberg, David, Jacobsen, Soren, Jayne, David, Kuhn, Annegret, Le Guern, Veronique, Lerstrøm, Kirsten, Levy, Roger, Machado-Ribeiro, Francinne, Mariette, Xavier, Missaykeh, Jamil, Morand, Eric, Mosca, Marta, Inanc, Murat, Navarra, Sandra, Neumann, Irmgard, Olesinska, Marzena, Petri, Michelle, Rahman, Anisur, Rekvig, Ole Petter, Rovensky, Jozef, Shoenfeld, Yehuda, Smolen, Josef, Tincani, Angela, Urowitz, Murray, van Leeuw, Bernadette, Vasconcelos, Carlos, Voss, Anne, Werth, Victoria P, Zakharova, Helena, Zoma, Asad, Schneider, Matthias, and Ward, Michael
- Published
- 2017
- Full Text
- View/download PDF
8. 03.15 Identification of novel micrornas in monocytes from rheumatoid arthritis and systemic sclerosis patients using next generation sequencing
- Author
-
Ciechomska, Marzena, Bonek, Krzysztof, Plaza, Anna, Gluszko, Piotr, Swacha, Monika, Olesinska, Marzena, Haase, Bettina, Benes, Vladimir, Wojtas, Bartosz, Kaminska, Bozena, and Maslinski, Wlodzimierz
- Published
- 2017
- Full Text
- View/download PDF
9. 2021 DORIS definition of remission in SLE: final recommendations from an international task force
- Author
-
van Vollenhoven, Ronald F, primary, Bertsias, George, additional, Doria, Andrea, additional, Isenberg, David, additional, Morand, Eric, additional, Petri, Michelle A, additional, Pons-Estel, Bernardo A, additional, Rahman, Anisur, additional, Ugarte-Gil, Manuel Francisco, additional, Voskuyl, Alexandre, additional, Arnaud, Laurent, additional, Bruce, Ian N, additional, Cervera, Ricard, additional, Costedoat-Chalumeau, Nathalie, additional, Gordon, Caroline, additional, Houssiau, Frédéric A, additional, Mosca, Marta, additional, Schneider, Matthias, additional, Ward, Michael M, additional, Alarcon, Graciela, additional, Aringer, Martin, additional, Askanase, Anca D, additional, Bae, Sang-Cheol, additional, Bootsma, Hendrika, additional, Boumpas, Dimitrios T, additional, Brunner, Hermine, additional, Clarke, Ann Elaine, additional, Coney, Cindy, additional, Czirják, László, additional, Dörner, Thomas, additional, Faria, Raquel, additional, Fischer, Rebecca, additional, Fritsch-Stork, Ruth, additional, Inanc, Murat, additional, Jacobsen, Søren, additional, Jayne, David, additional, Kuhn, Annegret, additional, van Leeuw, Bernadette, additional, Limper, Maarten, additional, Mariette, Xavier, additional, Navarra, Sandra, additional, Nikpour, Mandana, additional, Olesinska, Marzena Helena, additional, Pons-Estel, Guillermo, additional, Romero-Diaz, Juanita, additional, Rubio, Blanca, additional, Schoenfeld, Yehuda, additional, Bonfá, Eloisa, additional, Smolen, Josef, additional, Teng, Y K Onno, additional, Tincani, Angela, additional, Tsang-A-Sjoe, Michel, additional, Vasconcelos, Carlos, additional, Voss, Anne, additional, Werth, Victoria P, additional, Zakharhova, Elena, additional, and Aranow, Cynthia, additional
- Published
- 2021
- Full Text
- View/download PDF
10. An Overview of Neonatal Lupus with Anti-Ro Characteristics
- Author
-
Gryka-Marton, Malgorzata, primary, Szukiewicz, Dariusz, additional, Teliga-Czajkowska, Justyna, additional, and Olesinska, Marzena, additional
- Published
- 2021
- Full Text
- View/download PDF
11. IL-1β, IL-10 and TNF-α polymorphisms may affect systemic lupus erythematosus risk and phenotype
- Author
-
Rzeszotarska, Ewa, primary, Sowinska, Anna, additional, Stypinska, Barbara, additional, Lutkowska, Anna, additional, Felis-Giemza, Anna, additional, Olesinska, Marzena, additional, Puszczewicz, Mariusz, additional, Majewski, Dominik, additional, Jagodzinski, Pawel Piotr, additional, Haładyj, Ewa, additional, and Paradowska-Gorycka, Agnieszka, additional
- Published
- 2021
- Full Text
- View/download PDF
12. 2021 DORIS definition of remission in SLE: final recommendations from an international task force.
- Author
-
UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, van Vollenhoven, Ronald F, Bertsias, George, Doria, Andrea, Isenberg, David, Morand, Eric, Petri, Michelle A, Pons-Estel, Bernardo A, Rahman, Anisur, Ugarte-Gil, Manuel Francisco, Voskuyl, Alexandre, Arnaud, Laurent, Bruce, Ian N, Cervera, Ricard, Costedoat-Chalumeau, Nathalie, Gordon, Caroline, Houssiau, Frédéric, Mosca, Marta, Schneider, Matthias, Ward, Michael M, Alarcon, Graciela, Aringer, Martin, Askenase, Anka, Bae, Sang-Cheol, Bootsma, Hendrika, Boumpas, Dimitrios T, Brunner, Hermine, Clarke, Ann Elaine, Coney, Cindy, Czirják, László, Dörner, Thomas, Faria, Raquel, Fischer, Rebecca, Fritsch-Stork, Ruth, Inanc, Murat, Jacobsen, Søren, Jayne, David, Kuhn, Annegret, van Leeuw, Bernadette, Limper, Maarten, Mariette, Xavier, Navarra, Sandra, Nikpour, Mandana, Olesinska, Marzena Helena, Pons-Estel, Guillermo, Romero-Diaz, Juanita, Rubio, Blanca, Schoenfeld, Yehuda, Bonfá, Eloisa, Smolen, Josef, Teng, Y K Onno, Tincani, Angela, Tsang-A-Sjoe, Michel, Vasconcelos, Carlos, Voss, Anne, Werth, Victoria P, Zakharhova, Elena, Aranow, Cynthia, UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, van Vollenhoven, Ronald F, Bertsias, George, Doria, Andrea, Isenberg, David, Morand, Eric, Petri, Michelle A, Pons-Estel, Bernardo A, Rahman, Anisur, Ugarte-Gil, Manuel Francisco, Voskuyl, Alexandre, Arnaud, Laurent, Bruce, Ian N, Cervera, Ricard, Costedoat-Chalumeau, Nathalie, Gordon, Caroline, Houssiau, Frédéric, Mosca, Marta, Schneider, Matthias, Ward, Michael M, Alarcon, Graciela, Aringer, Martin, Askenase, Anka, Bae, Sang-Cheol, Bootsma, Hendrika, Boumpas, Dimitrios T, Brunner, Hermine, Clarke, Ann Elaine, Coney, Cindy, Czirják, László, Dörner, Thomas, Faria, Raquel, Fischer, Rebecca, Fritsch-Stork, Ruth, Inanc, Murat, Jacobsen, Søren, Jayne, David, Kuhn, Annegret, van Leeuw, Bernadette, Limper, Maarten, Mariette, Xavier, Navarra, Sandra, Nikpour, Mandana, Olesinska, Marzena Helena, Pons-Estel, Guillermo, Romero-Diaz, Juanita, Rubio, Blanca, Schoenfeld, Yehuda, Bonfá, Eloisa, Smolen, Josef, Teng, Y K Onno, Tincani, Angela, Tsang-A-Sjoe, Michel, Vasconcelos, Carlos, Voss, Anne, Werth, Victoria P, Zakharhova, Elena, and Aranow, Cynthia
- Abstract
OBJECTIVE: To achieve consensus on a definition of remission in SLE (DORIS). BACKGROUND: Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. METHODS: Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. RESULTS: Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator's Global Assessment <0.5 (0-3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. CONCLUSION: The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.
- Published
- 2021
13. 2021 DORIS definition of remission in SLE:Final recommendations from an international task force
- Author
-
van Vollenhoven, Ronald F., Bertsias, George, Doria, Andrea, Isenberg, David, Morand, Eric, Petri, Michelle A., Pons-Estel, Bernardo A., Rahman, Anisur, Ugarte-Gil, Manuel Francisco, Voskuyl, Alexandre, Arnaud, Laurent, Bruce, Ian N., Cervera, Ricard, Costedoat-Chalumeau, Nathalie, Gordon, Caroline, Houssiau, Frédéric A., Mosca, Marta, Schneider, Matthias, Ward, Michael M., Alarcon, Graciela, Aringer, Martin, Askenase, Anka, Bae, Sang Cheol, Bootsma, Hendrika, Boumpas, Dimitrios T., Brunner, Hermine, Clarke, Ann Elaine, Coney, Cindy, Czirják, László, Dörner, Thomas, Faria, Raquel, Fischer, Rebecca, Fritsch-Stork, Ruth, Inanc, Murat, Jacobsen, Søren, Jayne, David, Kuhn, Annegret, van Leeuw, Bernadette, Limper, Maarten, Mariette, Xavier, Navarra, Sandra, Nikpour, Mandana, Olesinska, Marzena Helena, Pons-Estel, Guillermo, Romero-Diaz, Juanita, Rubio, Blanca, Schoenfeld, Yehuda, Bonfá, Eloisa, Smolen, Josef, Teng, Y. K.Onno, Tincani, Angela, Tsang-A-Sjoe, Michel, Vasconcelos, Carlos, Voss, Anne, Werth, Victoria P., Zakharhova, Elena, Aranow, Cynthia, van Vollenhoven, Ronald F., Bertsias, George, Doria, Andrea, Isenberg, David, Morand, Eric, Petri, Michelle A., Pons-Estel, Bernardo A., Rahman, Anisur, Ugarte-Gil, Manuel Francisco, Voskuyl, Alexandre, Arnaud, Laurent, Bruce, Ian N., Cervera, Ricard, Costedoat-Chalumeau, Nathalie, Gordon, Caroline, Houssiau, Frédéric A., Mosca, Marta, Schneider, Matthias, Ward, Michael M., Alarcon, Graciela, Aringer, Martin, Askenase, Anka, Bae, Sang Cheol, Bootsma, Hendrika, Boumpas, Dimitrios T., Brunner, Hermine, Clarke, Ann Elaine, Coney, Cindy, Czirják, László, Dörner, Thomas, Faria, Raquel, Fischer, Rebecca, Fritsch-Stork, Ruth, Inanc, Murat, Jacobsen, Søren, Jayne, David, Kuhn, Annegret, van Leeuw, Bernadette, Limper, Maarten, Mariette, Xavier, Navarra, Sandra, Nikpour, Mandana, Olesinska, Marzena Helena, Pons-Estel, Guillermo, Romero-Diaz, Juanita, Rubio, Blanca, Schoenfeld, Yehuda, Bonfá, Eloisa, Smolen, Josef, Teng, Y. K.Onno, Tincani, Angela, Tsang-A-Sjoe, Michel, Vasconcelos, Carlos, Voss, Anne, Werth, Victoria P., Zakharhova, Elena, and Aranow, Cynthia
- Abstract
Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. Methods Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. Results Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator’s Global Assessment <0.5 (0–3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. Conclusion The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.
- Published
- 2021
14. Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity
- Author
-
Mielnik, Pawel, Chwalinska-Sadowska, Hanna, Wiesik-Szewczyk, Ewa, Maslinski, Wlodzimierz, and Olesinska, Marzena
- Published
- 2012
- Full Text
- View/download PDF
15. Tocilizumab in systemic sclerosis:a randomised, double-blind, placebo-controlled, phase 3 trial
- Author
-
Khanna, Dinesh, Lin, Celia J.F., Furst, Daniel E., Goldin, Jonathan, Kim, Grace, Kuwana, Masataka, Allanore, Yannick, Matucci-Cerinic, Marco, Distler, Oliver, Shima, Yoshihito, van Laar, Jacob M., Spotswood, Helen, Wagner, Bridget, Siegel, Jeffrey, Jahreis, Angelika, Denton, Christopher P., Lucero, Eleonora, Pons-Estel, Bernardo, Rivero, Mariano, Tate, Guillermo, Smith, Vanessa, De Langhe, Ellen, Rashkov, Rasho, Batalov, Anastas, Goranov, Ivan, Stoilov, Rumen, Dunne, James, Johnson, Sindhu R., Pope, Janet E., Martinović Kaliterna, Dušanka, Mogensen, Mette, Olesen, Anne Braae, Henes, Joerg Christoph, Müller-Ladner, Ulf, Riemekasten, Gabriela, Skapenko, Alla, Vlachoyiannopoulos, Panayiotis, Kiss, Emese, Minier, Tünde, Beretta, Lorenzo, Gremese, Elisa, Valentini, Gabriele, Asano, Yoshihide, Atsumi, Tatsuya, Ihn, Hironobu, Ishii, Tomonori, Ishikawa, Osamu, Takahashi, Hiroki, Takehara, Kazuhiko, Tanaka, Yoshiya, Yamasaki, Yoshioki, Bukauskiene, Loreta, Butrimiene, Irena, Medrano Ramirez, Gabriel, Ramos-Remus, Cesar, Sofia Rodriguez Reyna, Tatiana, de Vries-Bouwstra, Jeska, Batko, Bogdan, Jeka, Slawomir, Kucharz, Eugeniusz, Majdan, Maria, Olesinska, Marzena, Smolenska, Zaneta, Alves, Jose, Santos, Maria, Mihai, Carmen Marina, Rednic, Simona, Castellvi Barranco, Ivan, Lopez Longo, Francisco Javier, Simeon Aznar, Carmen, Carreira, Patricia, Walker, Ulrich A., Derrett-Smith, Emma, Griffiths, Bridget, McKay, Neil, Aelion, Jacob, Borofsky, Michael, Fleischmann, Roy, Forstot, Joseph Z., Kafaja, Suzanne, Khan, M. Faisal, Kohen, Michael D., Martin, Richard W., Mendoza-Ballesteros, Fabian, Nami, Alireza, Pang, Shirley, Rios, Grissel, Simms, Robert, Sullivan, Keith Michael, Steen, Virginia D., Khanna, Dinesh, Lin, Celia J.F., Furst, Daniel E., Goldin, Jonathan, Kim, Grace, Kuwana, Masataka, Allanore, Yannick, Matucci-Cerinic, Marco, Distler, Oliver, Shima, Yoshihito, van Laar, Jacob M., Spotswood, Helen, Wagner, Bridget, Siegel, Jeffrey, Jahreis, Angelika, Denton, Christopher P., Lucero, Eleonora, Pons-Estel, Bernardo, Rivero, Mariano, Tate, Guillermo, Smith, Vanessa, De Langhe, Ellen, Rashkov, Rasho, Batalov, Anastas, Goranov, Ivan, Stoilov, Rumen, Dunne, James, Johnson, Sindhu R., Pope, Janet E., Martinović Kaliterna, Dušanka, Mogensen, Mette, Olesen, Anne Braae, Henes, Joerg Christoph, Müller-Ladner, Ulf, Riemekasten, Gabriela, Skapenko, Alla, Vlachoyiannopoulos, Panayiotis, Kiss, Emese, Minier, Tünde, Beretta, Lorenzo, Gremese, Elisa, Valentini, Gabriele, Asano, Yoshihide, Atsumi, Tatsuya, Ihn, Hironobu, Ishii, Tomonori, Ishikawa, Osamu, Takahashi, Hiroki, Takehara, Kazuhiko, Tanaka, Yoshiya, Yamasaki, Yoshioki, Bukauskiene, Loreta, Butrimiene, Irena, Medrano Ramirez, Gabriel, Ramos-Remus, Cesar, Sofia Rodriguez Reyna, Tatiana, de Vries-Bouwstra, Jeska, Batko, Bogdan, Jeka, Slawomir, Kucharz, Eugeniusz, Majdan, Maria, Olesinska, Marzena, Smolenska, Zaneta, Alves, Jose, Santos, Maria, Mihai, Carmen Marina, Rednic, Simona, Castellvi Barranco, Ivan, Lopez Longo, Francisco Javier, Simeon Aznar, Carmen, Carreira, Patricia, Walker, Ulrich A., Derrett-Smith, Emma, Griffiths, Bridget, McKay, Neil, Aelion, Jacob, Borofsky, Michael, Fleischmann, Roy, Forstot, Joseph Z., Kafaja, Suzanne, Khan, M. Faisal, Kohen, Michael D., Martin, Richard W., Mendoza-Ballesteros, Fabian, Nami, Alireza, Pang, Shirley, Rios, Grissel, Simms, Robert, Sullivan, Keith Michael, and Steen, Virginia D.
- Abstract
Background: A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in systemic sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial lung disease (SSc-ILD) in a phase 3 trial to investigate the safety and efficacy of tocilizumab, an anti-interleukin-6 receptor antibody, in the treatment of systemic sclerosis. Methods: In this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, participants were recruited from 75 sites in 20 countries across Europe, North America, Latin America, and Japan. Adults with diffuse cutaneous systemic sclerosis for 60 months or less and a modified Rodnan skin score (mRSS) of 10–35 at screening were randomly assigned (1:1) with a voice-web-response system to receive subcutaneous tocilizumab 162 mg or placebo weekly for 48 weeks, stratified by IL-6 levels; participants and investigators were masked to treatment group. The primary endpoint was the difference in change from baseline to week 48 in mRSS. Percentage of predicted forced vital capacity (FVC% predicted) at week 48, time to treatment failure, and patient-reported and physician-reported outcomes were secondary endpoints. This trial is registered with ClinicalTrials.gov (number NCT02453256) and is closed to accrual. Findings: Between Nov 20, 2015, and Feb 14, 2017, 210 individuals were randomly assigned to receive tocilizumab (n=104) or placebo (n=106). In the intention-to-treat population, least squares mean [LSM] change from baseline to week 48 in mRSS was −6·14 for tocilizumab and −4·41 for placebo (adjusted difference −1·73 [95% CI −3·78 to 0·32]; p=0·10). The shift in distribution of change from baseline in FVC% predicted at week 48 favoured tocilizumab (van Elteren nominal p=0·002 vs placebo), with a difference in LSM of 4·2 (95% CI 2·0–6·4; nominal p=0·0002), as did time to treatment failure (hazard ratio 0·63 [95% CI 0·37–1·06]; nominal p=0·08). Change in LSM from baseline to week 48 in Health Assessment Ques
- Published
- 2020
16. Extraskeletal Manifestations in Rheumatoid Arthritis - Clinical Cases
- Author
-
Romanowska-Prochnicka, Katarzyna, primary, Rzodkiewicz, Przemysaw, additional, Olesinska, Marzena, additional, Szukiewicz, Dariusz, additional, and Maslinski, Sawomir, additional
- Published
- 2013
- Full Text
- View/download PDF
17. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
- Author
-
Khanna, Dinesh, primary, Lin, Celia J F, additional, Furst, Daniel E, additional, Goldin, Jonathan, additional, Kim, Grace, additional, Kuwana, Masataka, additional, Allanore, Yannick, additional, Matucci-Cerinic, Marco, additional, Distler, Oliver, additional, Shima, Yoshihito, additional, van Laar, Jacob M, additional, Spotswood, Helen, additional, Wagner, Bridget, additional, Siegel, Jeffrey, additional, Jahreis, Angelika, additional, Denton, Christopher P, additional, Lucero, Eleonora, additional, Pons-Estel, Bernardo, additional, Rivero, Mariano, additional, Tate, Guillermo, additional, Smith, Vanessa, additional, De Langhe, Ellen, additional, Rashkov, Rasho, additional, Batalov, Anastas, additional, Goranov, Ivan, additional, Stoilov, Rumen, additional, Dunne, James, additional, Johnson, Sindhu R., additional, Pope, Janet E., additional, Martinović Kaliterna, Dušanka, additional, Mogensen, Mette, additional, Olesen, Anne Braae, additional, Henes, Joerg Christoph, additional, Müller-Ladner, Ulf, additional, Riemekasten, Gabriela, additional, Skapenko, Alla, additional, Vlachoyiannopoulos, Panayiotis, additional, Kiss, Emese, additional, Minier, Tünde, additional, Beretta, Lorenzo, additional, Gremese, Elisa, additional, Valentini, Gabriele, additional, Asano, Yoshihide, additional, Atsumi, Tatsuya, additional, Ihn, Hironobu, additional, Ishii, Tomonori, additional, Ishikawa, Osamu, additional, Takahashi, Hiroki, additional, Takehara, Kazuhiko, additional, Tanaka, Yoshiya, additional, Yamasaki, Yoshioki, additional, Bukauskiene, Loreta, additional, Butrimiene, Irena, additional, Medrano Ramirez, Gabriel, additional, Ramos-Remus, Cesar, additional, Sofia Rodriguez Reyna, Tatiana, additional, de Vries-Bouwstra, Jeska, additional, van Laar, Jacob M., additional, Batko, Bogdan, additional, Jeka, Slawomir, additional, Kucharz, Eugeniusz, additional, Majdan, Maria, additional, Olesinska, Marzena, additional, Smolenska, Zaneta, additional, Alves, Jose, additional, Santos, Maria, additional, Mihai, Carmen Marina, additional, Rednic, Simona, additional, Castellvi Barranco, Ivan, additional, Lopez Longo, Francisco Javier, additional, Simeon Aznar, Carmen, additional, Carreira, Patricia, additional, Walker, Ulrich A., additional, Derrett-Smith, Emma, additional, Griffiths, Bridget, additional, McKay, Neil, additional, Denton, Christopher P., additional, Aelion, Jacob, additional, Borofsky, Michael, additional, Fleischmann, Roy, additional, Forstot, Joseph Z., additional, Furst, Daniel E., additional, Kafaja, Suzanne, additional, Khan, M. Faisal, additional, Khanna, Dinesh, additional, Kohen, Michael D., additional, Martin, Richard W., additional, Mendoza-Ballesteros, Fabian, additional, Nami, Alireza, additional, Pang, Shirley, additional, Rios, Grissel, additional, Simms, Robert, additional, Sullivan, Keith Michael, additional, and Steen, Virginia D., additional
- Published
- 2020
- Full Text
- View/download PDF
18. The Role of MECP2 and CCR5 Polymorphisms on the Development and Course of Systemic Lupus Erythematosus
- Author
-
Rzeszotarska, Ewa, primary, Sowinska, Anna, additional, Stypinska, Barbara, additional, Walczuk, Ewa, additional, Wajda, Anna, additional, Lutkowska, Anna, additional, Felis-Giemza, Anna, additional, Olesinska, Marzena, additional, Puszczewicz, Mariusz, additional, Majewski, Dominik, additional, Jagodzinski, Pawel Piotr, additional, Czerewaty, Michal, additional, Malinowski, Damian, additional, Pawlik, Andrzej, additional, Jaronczyk, Malgorzata, additional, and Paradowska-Gorycka, Agnieszka, additional
- Published
- 2020
- Full Text
- View/download PDF
19. Global miRNA and mRNA expression profiles identify miRNA‐26a‐2‐3p‐dependent repression of IFN signature in systemic sclerosis human monocytes
- Author
-
Ciechomska, Marzena, primary, Wojtas, Bartosz, additional, Swacha, Monika, additional, Olesinska, Marzena, additional, Benes, Vladimir, additional, and Maslinski, Wlodzimierz, additional
- Published
- 2020
- Full Text
- View/download PDF
20. The Serum Cell-Free microRNA Expression Profile in MCTD, SLE, SSc, and RA Patients
- Author
-
Stypinska, Barbara, primary, Wajda, Anna, additional, Walczuk, Ewa, additional, Olesinska, Marzena, additional, Lewandowska, Aleksandra, additional, Walczyk, Marcela, additional, and Paradowska-Gorycka, Agnieszka, additional
- Published
- 2020
- Full Text
- View/download PDF
21. KDR (VEGFR2) Genetic Variants and Serum Levels in Patients with Rheumatoid Arthritis
- Author
-
Paradowska-Gorycka, Agnieszka, primary, Stypinska, Barbara, additional, Pawlik, Andrzej, additional, Malinowski, Damian, additional, Romanowska-Prochnicka, Katarzyna, additional, Manczak, Malgorzata, additional, and Olesinska, Marzena, additional
- Published
- 2019
- Full Text
- View/download PDF
22. Neutrophil extracellular traps generation and degradation in patients with granulomatosis with polyangiitis and systemic lupus erythematosus
- Author
-
Pruchniak, Michal Przemyslaw, primary, Ostafin, Magdalena, additional, Wachowska, Malgorzata, additional, Jakubaszek, Michal, additional, Kwiatkowska, Brygida, additional, Olesinska, Marzena, additional, Zycinska, Katarzyna, additional, and Demkow, Urszula, additional
- Published
- 2019
- Full Text
- View/download PDF
23. Lack of association between rheumatoid arthritis and genetic variants rs10889677, rs11209026 and rs2201841 of IL-23R gene
- Author
-
Paradowska-Gorycka, Agnieszka, primary, Malinowski, Damian, additional, Haladyj, Ewa, additional, Olesinska, Marzena, additional, Safranow, Krzysztof, additional, and Pawlik, Andrzej, additional
- Published
- 2018
- Full Text
- View/download PDF
24. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS).
- Author
-
UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, van Vollenhoven, Ronald, Voskuyl, Alexandre, Bertsias, George, Aranow, Cynthia, Aringer, Martin, Arnaud, Laurent, Askanase, Anca, Balážová, Petra, Bonfa, Eloisa, Bootsma, Hendrika, Boumpas, Dimitrios, Bruce, Ian, Cervera, Ricard, Clarke, Ann, Coney, Cindy, Costedoat-Chalumeau, Nathalie, Czirják, László, Derksen, Ronald, Doria, Andrea, Dörner, Thomas, Fischer-Betz, Rebecca, Fritsch-Stork, Ruth, Gordon, Caroline, Graninger, Winfried, Györi, Noémi, Houssiau, Frédéric, Isenberg, David, Jacobsen, Soren, Jayne, David, Kuhn, Annegret, Le Guern, Veronique, Lerstrøm, Kirsten, Levy, Roger, Machado-Ribeiro, Francinne, Mariette, Xavier, Missaykeh, Jamil, Morand, Eric, Mosca, Marta, Inanc, Murat, Navarra, Sandra, Neumann, Irmgard, Olesinska, Marzena, Petri, Michelle, Rahman, Anisur, Rekvig, Ole Petter, Rovensky, Jozef, Shoenfeld, Yehuda, Smolen, Josef, Tincani, Angela, Urowitz, Murray, van Leeuw, Bernadette, Vasconcelos, Carlos, Voss, Anne, Werth, Victoria P, Zakharova, Helena, Zoma, Asad, Schneider, Matthias, Ward, Michael, UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, van Vollenhoven, Ronald, Voskuyl, Alexandre, Bertsias, George, Aranow, Cynthia, Aringer, Martin, Arnaud, Laurent, Askanase, Anca, Balážová, Petra, Bonfa, Eloisa, Bootsma, Hendrika, Boumpas, Dimitrios, Bruce, Ian, Cervera, Ricard, Clarke, Ann, Coney, Cindy, Costedoat-Chalumeau, Nathalie, Czirják, László, Derksen, Ronald, Doria, Andrea, Dörner, Thomas, Fischer-Betz, Rebecca, Fritsch-Stork, Ruth, Gordon, Caroline, Graninger, Winfried, Györi, Noémi, Houssiau, Frédéric, Isenberg, David, Jacobsen, Soren, Jayne, David, Kuhn, Annegret, Le Guern, Veronique, Lerstrøm, Kirsten, Levy, Roger, Machado-Ribeiro, Francinne, Mariette, Xavier, Missaykeh, Jamil, Morand, Eric, Mosca, Marta, Inanc, Murat, Navarra, Sandra, Neumann, Irmgard, Olesinska, Marzena, Petri, Michelle, Rahman, Anisur, Rekvig, Ole Petter, Rovensky, Jozef, Shoenfeld, Yehuda, Smolen, Josef, Tincani, Angela, Urowitz, Murray, van Leeuw, Bernadette, Vasconcelos, Carlos, Voss, Anne, Werth, Victoria P, Zakharova, Helena, Zoma, Asad, Schneider, Matthias, and Ward, Michael
- Abstract
OBJECTIVES: Treat-to-target recommendations have identified 'remission' as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE. METHODS: An international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%. RESULTS: The task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions:1. Definitions of remission will be worded as follows: remission in SLE is a durable state characterised by …………………. (reference to symptoms, signs, routine labs).2. For defining remission, a validated index must be used, for example, clinical systemic lupus erythematosus disease activity index (SLEDAI)=0, British Isles lupus assessment group (BILAG) 2004 D/E only, clinical European consensus lupus outcome measure (ECLAM)=0; with routine laboratory assessments included, and supplemented with physician's global assessment.3. Distinction is made between remission off and on therapy: remission off therapy requires the patient to be on no other treatment for SLE than maintenance antimalarials; and remission on therapy allows patients to be on stable maintenance antimalarials, low-dose corticosteroids (prednisone ≤5 mg/day), maintenance immunosuppressives and/or maintenance biologics.The task force also agreed that the most appropriate outcomes (dependent variables) for testing the prognostic value (construct validity) of potential remission definitions are: death, damage, flares and measures of health-related quality of life. CONCLUSIONS: The work of this international task force provides a framework for testing different definitions of remission against long-term outcomes.
- Published
- 2017
25. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups
- Author
-
Cluster B, Child Health, Infection & Immunity, Lundberg, Ingrid E, Tjärnlund, Anna, Bottai, Matteo, Werth, Victoria P, Pilkington, Clarissa, de Visser, Marianne, Alfredsson, Lars, Amato, Anthony A, Barohn, Richard J, Liang, Matthew H., Singh, Jasvinder A., Aggarwal, Rohit, Arnardottir, Snjolaug, Chinoy, Hector, Cooper, Robert G., Dankó, Katalin, Dimachkie, Mazen, Feldman, Brian M., Garcia-De La Torre, Ignacio, Gordon, Patrick, Hayashi, Taichi, Katz, James D, Kohsaka, Hitoshi, Lachenbruch, Peter A., Lang, Bianca A, Li, Yuhui, Oddis, Chester V., Olesinska, Marzena, Reed, Ann M., Rutkowska-Sak, Lidia, Sanner, Helga, Selva-O'Callaghan, Albert, Song, Yeong-Wook, Vencovsky, Jiri, Ytterberg, Steven R., Miller, Frederick W., Rider, Lisa G., International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland), van Royen, Annet, Cluster B, Child Health, Infection & Immunity, Lundberg, Ingrid E, Tjärnlund, Anna, Bottai, Matteo, Werth, Victoria P, Pilkington, Clarissa, de Visser, Marianne, Alfredsson, Lars, Amato, Anthony A, Barohn, Richard J, Liang, Matthew H., Singh, Jasvinder A., Aggarwal, Rohit, Arnardottir, Snjolaug, Chinoy, Hector, Cooper, Robert G., Dankó, Katalin, Dimachkie, Mazen, Feldman, Brian M., Garcia-De La Torre, Ignacio, Gordon, Patrick, Hayashi, Taichi, Katz, James D, Kohsaka, Hitoshi, Lachenbruch, Peter A., Lang, Bianca A, Li, Yuhui, Oddis, Chester V., Olesinska, Marzena, Reed, Ann M., Rutkowska-Sak, Lidia, Sanner, Helga, Selva-O'Callaghan, Albert, Song, Yeong-Wook, Vencovsky, Jiri, Ytterberg, Steven R., Miller, Frederick W., Rider, Lisa G., International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland), and van Royen, Annet
- Published
- 2017
26. A framework for remission in SLE:consensus findings from a large international task force on definitions of remission in SLE (DORIS)
- Author
-
van Vollenhoven, Ronald, Voskuyl, Alexandre, Bertsias, George, Aranow, Cynthia, Aringer, Martin, Arnaud, Laurent, Askanase, Anca, Balážová, Petra, Bonfa, Eloisa, Bootsma, Hendrika, Boumpas, Dimitrios, Bruce, Ian, Cervera, Ricard, Clarke, Ann, Coney, Cindy, Costedoat-Chalumeau, Nathalie, Czirják, László, Derksen, Ronald, Doria, Andrea, Dörner, Thomas, Fischer-Betz, Rebecca, Fritsch-Stork, Ruth, Gordon, Caroline, Graninger, Winfried, Györi, Noémi, Houssiau, Frédéric, Isenberg, David, Jacobsen, Soren, Jayne, David, Kuhn, Annegret, Le Guern, Veronique, Lerstrøm, Kirsten, Levy, Roger, Machado-Ribeiro, Francinne, Mariette, Xavier, Missaykeh, Jamil, Morand, Eric, Mosca, Marta, Inanc, Murat, Navarra, Sandra, Neumann, Irmgard, Olesinska, Marzena, Petri, Michelle, Rahman, Anisur, Rekvig, Ole Petter, Rovensky, Jozef, Shoenfeld, Yehuda, Smolen, Josef, Tincani, Angela, Urowitz, Murray, van Leeuw, Bernadette, Vasconcelos, Carlos, Voss, Anne, Werth, Victoria P, Zakharova, Helena, Zoma, Asad, Schneider, Matthias, Ward, Michael, van Vollenhoven, Ronald, Voskuyl, Alexandre, Bertsias, George, Aranow, Cynthia, Aringer, Martin, Arnaud, Laurent, Askanase, Anca, Balážová, Petra, Bonfa, Eloisa, Bootsma, Hendrika, Boumpas, Dimitrios, Bruce, Ian, Cervera, Ricard, Clarke, Ann, Coney, Cindy, Costedoat-Chalumeau, Nathalie, Czirják, László, Derksen, Ronald, Doria, Andrea, Dörner, Thomas, Fischer-Betz, Rebecca, Fritsch-Stork, Ruth, Gordon, Caroline, Graninger, Winfried, Györi, Noémi, Houssiau, Frédéric, Isenberg, David, Jacobsen, Soren, Jayne, David, Kuhn, Annegret, Le Guern, Veronique, Lerstrøm, Kirsten, Levy, Roger, Machado-Ribeiro, Francinne, Mariette, Xavier, Missaykeh, Jamil, Morand, Eric, Mosca, Marta, Inanc, Murat, Navarra, Sandra, Neumann, Irmgard, Olesinska, Marzena, Petri, Michelle, Rahman, Anisur, Rekvig, Ole Petter, Rovensky, Jozef, Shoenfeld, Yehuda, Smolen, Josef, Tincani, Angela, Urowitz, Murray, van Leeuw, Bernadette, Vasconcelos, Carlos, Voss, Anne, Werth, Victoria P, Zakharova, Helena, Zoma, Asad, Schneider, Matthias, and Ward, Michael
- Abstract
OBJECTIVES: Treat-to-target recommendations have identified 'remission' as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE.METHODS: An international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%.RESULTS: The task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions:1. Definitions of remission will be worded as follows: remission in SLE is a durable state characterised by …………………. (reference to symptoms, signs, routine labs).2. For defining remission, a validated index must be used, for example, clinical systemic lupus erythematosus disease activity index (SLEDAI)=0, British Isles lupus assessment group (BILAG) 2004 D/E only, clinical European consensus lupus outcome measure (ECLAM)=0; with routine laboratory assessments included, and supplemented with physician's global assessment.3. Distinction is made between remission off and on therapy: remission off therapy requires the patient to be on no other treatment for SLE than maintenance antimalarials; and remission on therapy allows patients to be on stable maintenance antimalarials, low-dose corticosteroids (prednisone ≤5 mg/day), maintenance immunosuppressives and/or maintenance biologics.The task force also agreed that the most appropriate outcomes (dependent variables) for testing the prognostic value (construct validity) of potential remission definitions are: death, damage, flares and measures of health-related quality of life.CONCLUSIONS: The work of this international task force provides a framework for testing different definitions of remission against long-term outcomes.
- Published
- 2017
27. Proposal for a Candidate Core Set of Fitness and Strength Tests for Patients with Childhood or Adult Idiopathic Inflammatory Myopathies
- Author
-
van der Stap, Djamilla K D, Rider, Lisa G, Feldman, Brian M, Houghton, Kristin M, Singh-Grewal, Davinder, Kutzbach, Abraham Garcia, Munters, Li Alemo, Takken, Tim, Alexanderson, Helene, Huber, Adam M, Gualano, Bruno, Gordon, Patrick, van der Net, Janjaap, Mathiesen, Pernille, Johnson, Liam G, Ernste, Floranne C, Arboleya, Luis, Barohn, Richard, van Brussel, Marco, Chinoy, Hector, Chung, Lorinda, Cooper, Robert, Dimachkie, Mazen, Finkel, Richard, La Torre, Ignacio Garcia-De, Gono, Takahisa, Griffin, Thomas, International_Myositis_Assessment_and_Clinical_Studies_Group), Kawasumi, Hidenaga, Khubchandani, Raju, Lundberg, Ingrid, Mastaglia, Frank, Maurer, Britta, McCann, Liza, Needham, Merrille, Olesinska, Marzena, Olsen, Nancy, van Royen-Kerkhof, Annet, Rutkowska-Sak, Lidia, Saad-Magalhaes, Claudia, Sallum, Adriana, Sanner, Helga, Selva-O'Callaghan, Albert, Silva, Clovis, Snejana, Vetrila, Song, Yeong-Wook, Vehe, Richard, Wortmann, Robert, University of Zurich, and Takken, Tim
- Subjects
Male ,FITNESS ,2745 Rheumatology ,Physical fitness ,Delphi method ,Review ,Severity of Illness Index ,Outcome measures ,CRIANÇAS ,0302 clinical medicine ,Fitness ,MYOSITIS ,Immunology and Allergy ,Medicine ,Child ,Netherlands ,Age Factors ,10051 Rheumatology Clinic and Institute of Physical Medicine ,Exercise Therapy ,Idiopathic inflammatory myopathies ,Practice Guidelines as Topic ,2723 Immunology and Allergy ,Female ,Adult ,medicine.medical_specialty ,Immunology ,610 Medicine & health ,EXERCISE ,Research Support ,Sensitivity and Specificity ,Article ,N.I.H ,03 medical and health sciences ,Sex Factors ,Physical medicine and rehabilitation ,Rheumatology ,Severity of illness ,Journal Article ,Humans ,Aerobic exercise ,Comparative Study ,Muscle Strength ,Exercise ,Intramural ,030203 arthritis & rheumatology ,Core set ,2403 Immunology ,Myositis ,business.industry ,OUTCOME MEASURES ,INSTRUMENTS ,Research Support, N.I.H., Intramural ,Physical Fitness ,Muscle strength ,Physical therapy ,business ,Instruments ,030217 neurology & neurosurgery - Abstract
Objective.Currently there are no evidence-based recommendations regarding fitness and strength tests for patients with childhood or adult idiopathic inflammatory myopathies (IIM). This hinders clinicians and researchers in choosing the appropriate fitness- or muscle strength-related outcome measures for these patients. Through a Delphi survey, we aimed to identify a candidate core set of fitness and strength tests for children and adults with IIM.Methods.Fifteen experts participated in a Delphi survey that consisted of 5 stages to achieve a consensus. Using an extensive search of published literature and through the work of experts, a candidate core set based on expert opinion and clinimetrics properties was developed. Members of the International Myositis Assessment and Clinical Studies Group were invited to review this candidate core set during the final stage, which led to a final candidate core set.Results.A core set of fitness- and strength-related outcome measures was identified for children and adults with IIM. For both children and adults, different tests were identified and selected for maximal aerobic fitness, submaximal aerobic fitness, anaerobic fitness, muscle strength tests, and muscle function tests.Conclusion.The core set of fitness- and strength-related outcome measures provided by this expert consensus process will assist practitioners and researchers in deciding which tests to use in patients with IIM. This will improve the uniformity of fitness and strength tests across studies, thereby facilitating the comparison of study results and therapeutic exercise program outcomes among patients with IIM.
- Published
- 2016
28. FLT-1 gene polymorphisms and protein expression profile in rheumatoid arthritis
- Author
-
Paradowska-Gorycka, Agnieszka, primary, Sowinska, Anna, additional, Pawlik, Andrzej, additional, Malinowski, Damian, additional, Stypinska, Barbara, additional, Haladyj, Ewa, additional, Romanowska-Prochnicka, Katarzyna, additional, and Olesinska, Marzena, additional
- Published
- 2017
- Full Text
- View/download PDF
29. 03.15 Identification of novel micrornas in monocytes from rheumatoid arthritis and systemic sclerosis patients using next generation sequencing
- Author
-
Ciechomska, Marzena, primary, Bonek, Krzysztof, additional, Plaza, Anna, additional, Gluszko, Piotr, additional, Swacha, Monika, additional, Olesinska, Marzena, additional, Haase, Bettina, additional, Benes, Vladimir, additional, Wojtas, Bartosz, additional, Kaminska, Bozena, additional, and Maslinski, Wlodzimierz, additional
- Published
- 2017
- Full Text
- View/download PDF
30. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
- Author
-
van Vollenhoven, Ronald, primary, Voskuyl, Alexandre, additional, Bertsias, George, additional, Aranow, Cynthia, additional, Aringer, Martin, additional, Arnaud, Laurent, additional, Askanase, Anca, additional, Balážová, Petra, additional, Bonfa, Eloisa, additional, Bootsma, Hendrika, additional, Boumpas, Dimitrios, additional, Bruce, Ian, additional, Cervera, Ricard, additional, Clarke, Ann, additional, Coney, Cindy, additional, Costedoat-Chalumeau, Nathalie, additional, Czirják, László, additional, Derksen, Ronald, additional, Doria, Andrea, additional, Dörner, Thomas, additional, Fischer-Betz, Rebecca, additional, Fritsch-Stork, Ruth, additional, Gordon, Caroline, additional, Graninger, Winfried, additional, Györi, Noémi, additional, Houssiau, Frédéric, additional, Isenberg, David, additional, Jacobsen, Soren, additional, Jayne, David, additional, Kuhn, Annegret, additional, Le Guern, Veronique, additional, Lerstrøm, Kirsten, additional, Levy, Roger, additional, Machado-Ribeiro, Francinne, additional, Mariette, Xavier, additional, Missaykeh, Jamil, additional, Morand, Eric, additional, Mosca, Marta, additional, Inanc, Murat, additional, Navarra, Sandra, additional, Neumann, Irmgard, additional, Olesinska, Marzena, additional, Petri, Michelle, additional, Rahman, Anisur, additional, Rekvig, Ole Petter, additional, Rovensky, Jozef, additional, Shoenfeld, Yehuda, additional, Smolen, Josef, additional, Tincani, Angela, additional, Urowitz, Murray, additional, van Leeuw, Bernadette, additional, Vasconcelos, Carlos, additional, Voss, Anne, additional, Werth, Victoria P, additional, Zakharova, Helena, additional, Zoma, Asad, additional, Schneider, Matthias, additional, and Ward, Michael, additional
- Published
- 2016
- Full Text
- View/download PDF
31. Relationship between VEGF Gene Polymorphisms and Serum VEGF Protein Levels in Patients with Rheumatoid Arthritis
- Author
-
Paradowska-Gorycka, Agnieszka, primary, Pawlik, Andrzej, additional, Romanowska-Prochnicka, Katarzyna, additional, Haladyj, Ewa, additional, Malinowski, Damian, additional, Stypinska, Barbara, additional, Manczak, Malgorzata, additional, and Olesinska, Marzena, additional
- Published
- 2016
- Full Text
- View/download PDF
32. Impact of the IL-17F, IL-23 and IL-23R on susceptibility and phenotype of systemic lupus erythematosus
- Author
-
Paradowska-Gorycka, Agnieszka, primary, Sowinska, Anna, additional, Stypinska, Barbara, additional, Grobelna, Malwina Katarzyna, additional, Walczyk, Marcela, additional, Olesinska, Marzena, additional, Piotrowski, Piotr, additional, and Jagodziński, Paweł Piotr, additional
- Published
- 2016
- Full Text
- View/download PDF
33. RORC2 Genetic Variants and Serum Levels in Patients with Rheumatoid Arthritis
- Author
-
Paradowska-Gorycka, Agnieszka, primary, Stypinska, Barbara, additional, Pawlik, Andrzej, additional, Romanowska-Prochnicka, Katarzyna, additional, Haladyj, Ewa, additional, Manczak, Malgorzata, additional, and Olesinska, Marzena, additional
- Published
- 2016
- Full Text
- View/download PDF
34. <italic>HIF-1A</italic> gene polymorphisms and its protein level in patients with rheumatoid arthritis: a case-control study.
- Author
-
Paradowska-Gorycka, Agnieszka, Stypinska, Barbara, Pawlik, Andrzej, Haladyj, Ewa, Romanowska-Próchnicka, Katarzyna, and Olesinska, Marzena
- Subjects
GENETIC polymorphisms ,RHEUMATOID arthritis ,HUMAN genetic variation ,SCURFIN (Protein) ,VASCULAR endothelial growth factors ,LINKAGE disequilibrium ,PATIENTS - Abstract
Objectives: The aim of the study was to identify
HIF-1A genetic variants and their possible association with HIF-1α, VEGF, KDR, RORc and Foxp3 protein levels, and susceptibility to and severity of RA.Methods: TheHIF-1A gene polymorphisms were genotyped for 587 RA patients and 341 healthy individuals. The HIF-1α, VEGF, KDR, RORc and Foxp3serum levels were evaluated.Results: Under the codominant model, the frequency of the genotype was lower in RA patients than in controls (rs12434438 GG P = 0.02). Under the recessive model (AA + AG vs GG), the association was also significant (OR 3.32; CI 1.19-9.24;P = 0.02). Overall, /rs12434438 A andG /rs1951795 A are in almost completed linkage disequilibrium withC D ′ = 0.96 andr 2 = 0.85. The allele was associated with rheumatoid factor (HIF-1A rs1951795 A P = 0.02) and mean value of erythrocyte sedimentation rate (ESR) (P = 0.05). In RA patients with genotype, the parameters of disease activity such as DAS-28, VAS score, Larsen score or HAQ score were lower compared to RA patients with theHIF-1A rs12434439 GG genotype. Moreover, we also observed that Foxp3 serum levels were higher, and RORc2 serum levels were lower in RA patients withHIF-1A rs12434439 AA .Conclusion: The polymorphicrs12434439 GG genotype may play a protective role for RA development. [ABSTRACT FROM AUTHOR]HIF-1A rs12434439 GG - Published
- 2018
- Full Text
- View/download PDF
35. Genetic Polymorphisms of Foxp3 in Patients with Rheumatoid Arthritis
- Author
-
Paradowska-Gorycka, Agnieszka, primary, Jurkowska, Monika, additional, Felis-Giemza, Anna, additional, Romanowska-Próchnicka, Katarzyna, additional, Manczak, Malgorzata, additional, Maslinski, Slawomir, additional, and Olesinska, Marzena, additional
- Published
- 2014
- Full Text
- View/download PDF
36. IL-10, IL-12B and IL-17 gene polymorphisms in patients with mixed connective tissue disease
- Author
-
Paradowska-Gorycka, Agnieszka, primary, Jurkowska, Monika, additional, Czuszynska, Zenobia, additional, Felis-Giemza, Anna, additional, Mańczak, Malgorzata, additional, Zdrojewski, Zbigniew, additional, and Olesinska, Marzena, additional
- Published
- 2014
- Full Text
- View/download PDF
37. Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity
- Author
-
Mielnik, Pawel, primary, Chwalinska-Sadowska, Hanna, additional, Wiesik-Szewczyk, Ewa, additional, Maslinski, Wlodzimierz, additional, and Olesinska, Marzena, additional
- Published
- 2010
- Full Text
- View/download PDF
38. Genetic Polymorphisms of Foxp3 in Patients with Rheumatoid Arthritis.
- Author
-
Paradowska-Gorycka, Agnieszka, Jurkowska, Monika, Felis-Giemza, Anna, Romanowska-Próchnicka, Katarzyna, Manczak, Malgorzata, Maslinski, Slawomir, and Olesinska, Marzena
- Published
- 2015
- Full Text
- View/download PDF
39. Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies
- Author
-
Mielnik, Pawel, primary, Wiesik-Szewczyk, Ewa, additional, Olesinska, Marzena, additional, Chwalinska-Sadowska, Hanna, additional, and Zabek, Jakub, additional
- Published
- 2006
- Full Text
- View/download PDF
40. Genetic Polymorphisms of Foxp3in Patients with Rheumatoid Arthritis
- Author
-
Paradowska-Gorycka, Agnieszka, Jurkowska, Monika, Felis-Giemza, Anna, Romanowska-Próchnicka, Katarzyna, Manczak, Malgorzata, Maslinski, Slawomir, and Olesinska, Marzena
- Abstract
Objective.The aim of the study was to identify 2 polymorphic variants in the promoter region of the Foxp3gene and their possible association with susceptibility to and severity of rheumatoid arthritis (RA). The association between genetic factors and pathogenesis suggests that T cells take part in the induction of RA. The CD4+CD25highFoxp3+ subset of regulatory T cells plays an essential role in preventing autoimmunity and maintaining immune homeostasis.Methods.Patients with RA (n = 274) and healthy individuals (n = 295) were examined for −3279 C/A and −924 A/G Foxp3gene polymorphisms by the polymerase chain reaction–restriction fragment-length polymorphism method. Serum Foxp3 levels in patients with RA and controls were measured with ELISA.Results.Foxp3−3279 A and −924 G alleles were associated with significantly elevated risk of RA in the population tested (p = 0.003 and p = 0.004, respectively) compared to the wild-type alleles. Overall, −3279 C/A and −924 A/G Foxp3gene polymorphisms were in indistinct linkage disequilibrium with D′ = 0.481 and r2= 0.225. From 4 possible haplotypes, frequencies of 2 (AG and CA) showed significant differences between both examined groups (respectively, p < 0.001 and p = 0.007). After appropriate adjustment of Bonferroni correction for multiple testing, the genotype-phenotype analysis showed no significant correlation of the Foxp3−3279 C/A and −924 A/G polymorphisms with the disease activity, joint damage, laboratory variables, and extraarticular manifestation in patients with RA. Serum Foxp3 level was significantly higher in patients than in controls (p < 0.0001).Conclusion.Current findings indicated that the Foxp3genetic polymorphism and the Foxp3 protein level may be associated with susceptibility to RA in the Polish population.
- Published
- 2015
- Full Text
- View/download PDF
41. IL-10, IL-12B and IL-17 gene polymorphisms in patients with mixed connective tissue disease.
- Author
-
Paradowska-Gorycka, Agnieszka, Jurkowska, Monika, Czuszynska, Zenobia, Felis-Giemza, Anna, Mańczak, Malgorzata, Zdrojewski, Zbigniew, and Olesinska, Marzena
- Subjects
MIXED connective tissue disease ,AUTOIMMUNE diseases ,CYTOKINES ,THROMBOCYTOPENIA ,SJOGREN'S syndrome - Abstract
Objectives. Mixed connective tissue disease (MCTD) is a rare systemic autoimmune disease with a prevalence of about 10 cases/100,000. It seems that in the pathogenesis of MCTD no individual cytokines/cells, but rather an altered pattern of these markers altogether may contribute to the autoimmune processes and their balance determines disease activity. IL-10, IL-12 and IL-17F as inflammatory cytokines might be an important functional candidate genes for autoimmune diseases including MCTD. Methods. The study group consisted of 66 patients with MCTD and of 106 (163 for IL-12B) healthy individuals. SNPs in the IL-10 (− 592C/A, − 1082G/A), IL-12B (+ 1188A/C) and IL-17F (His161Arg, Glu126Gly) genes were investigated by PCR-RFLP approach. Results. The frequency of the IL-10-592A and -1082A allele was higher in MCTD patients than in control groups (both p = 0,0000). In addition the -1082G/A IL-10 gene polymorphism was associated with esophageal involvement and with anti-U1-A and -C antibodies. The IL-17 7488A/G variant showed correlation with presence of anti-SmB and anti-dsDNA antibodies, while the IL-17F 7383A/G variant was associated with Sjögren's syndrome and leuco-and thrombocytopenia. Moreover, the IL-12 SNP + 1188A/C showed correlation with sclerodactyly in MCTD patients. Conclusion. Present findings indicate that IL-10 gene variants may be considered as genetic risk factors for MCTD susceptibility. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
42. Health-related quality of life impairment is equal for antiphospholipid syndrome whether primary or associated with systemic lupus erythematosus.
- Author
-
Haladyj, Ewa, Matusiewicz, Agata, Wysocki, Tomasz, and Olesinska, Marzena
- Subjects
- *
SYSTEMIC lupus erythematosus , *QUALITY of life , *VENOUS thrombosis , *POLISH people , *MISCARRIAGE , *ANTIPHOSPHOLIPID syndrome - Abstract
Introduction: Antiphospholipid syndrome (APS) manifests with thrombosis and pregnancy losses and may significantly impair the health-related quality of life (HRQoL). So far, APS has been perceived as a less burdensome disease than systemic lupus erythematosus (SLE), but data on this are scarce. The purpose of the present study was to evaluate HRQoL in APS patients by applying the Short Form 36 Health Survey (SF-36) and World Health Organization Quality-of-Life Scale (WHOQoL-BREF); to examine the impact of primary APS and with coexisting SLE (APS/SLE) on patient HRQoL; and to provide a description of the APS patient population. Material and methods: One hundred twelve patients with APS were included in the study, 57 of them with primary APS and 55 with coexisting SLE. HRQoL was measured by the 36-Item SF-36 and WHOQoL questionnaires. Results: Mean age was 47 years (47.6 ±13.8), and 96 patients were (85.7%) women. The mean disease duration was 72 months. Health-related quality of life impairment was found in both components for all APS patients in comparison to the healthy Polish population (p < 0.0001). There was no difference between APS and APS/SLE groups in HRQoL (mental component p = 1.0, physical component p = 0.337). The history of venous thrombosis was associated with HRQoL impairment only in the APS/SLE group in the physical component (p = 0.0118), not in primary APS (p = 0.6862). The mental component of SF-36 was associated with all domains of WHOQoL-BREF, while the physical component was associated only with physical health (p < 0.001). Conclusions: Primary APS and APS secondary to SLE lead to equal impairment in HRQoL. Diagnosis and proper management of all patients with APS are essential to prevent thrombosis and miscarriages, which ultimately will lead to longer survival with optimal life quality. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model
- Author
-
Alexandru Garaiman 1, Klaus Steigmiller 2, Catherine Gebhard 3, Carina Mihai 1, Rucsandra Dobrota 1, Cosimo Bruni 4, Marco Matucci-Cerinic 5, Joerg Henes 6, Jeska de Vries-Bouwstra 7, Vanessa Smith 8, Andrea Doria 9, Yannick Allanore 10, Lorenzo Dagna 11, Branimir Anić 12, Carlomaurizio Montecucco 13, Otylia Kowal-Bielecka 14, Mickael Martin 15, Yoshiya Tanaka 16, Anna-Maria Hoffmann-Vold 17, Ulrike Held 2, Oliver Distler 1, Mike Oliver Becker 1, EUSTAR Silvia Bellando Randone, Gemma Lepri, Ulrich Walker, Florenzo Iannone, Suzana Jordan, Radim Becvar, Ewa Gindzienska-Sieskiewicz, Katarzyna Karaszewska, Maurizio Cutolo, Giovanna Cuomo, Elise Siegert, Simona Rednic, Jérome Avouac, Carole Desbas, Roberto Caporali, Lorenzo Cavagna, Patricia E Carreira, Srdan Novak, László Czirják, Michele Iudici, Eugene J Kucharz, Elisabetta Zanatta, Bernard Coleiro, Gianluca Moroncini, Dominique Farge Bancel, Paolo Airò, Roger Hesselstr, Mislav Radic, Alexandra Balbir-Gurman, Nicolas Hunzelmann, Raffaele Pellerito, Alessandro Giollo, Jadranka Morovic-Vergles, Christopher Denton, Nemanja Damjanov, Ann-Christian Pecher, Vera Ortiz Santamaria, Stefan Heitmann, Dorota Krasowska, Paul Hasler, Ivan Foeldvari, Maria João Salvador, Bojana Stamenkovic, Carlo Francesco Selmi, Lidia P Ananieva, Ariane Herrick, Ulf Müller-Ladner, Raffaele De Palma, Merete Engelhart, Gabriela Szücs, Carlos de la Puente, Øyvind Midtvedt, Torhild Garen, Håvard Fretheim, Eric Hachulla, Valeria Riccieri, Ruxandra Maria Ionescu, Ana Maria Gheorghiu, Cord Sunderkötter, Jörg Distler, Francesca Ingegnoli, Luc Mouthon, Francesco Paolo Cantatore, Susanne Ullman, Maria Rosa Pozzi, Kilian Eyerich, Piotr Wiland, Marie Vanthuyne, Juan Jose Alegre-Sancho, Kristine Herrmann, Ellen De Langhe, Marko Baresic, Miroslav Mayer, Sule Yavuz, Brigitte Granel, Carolina de Souza Müller, Svetlana Agachi, Simon Stebbings, D'Alessandro Mathieu, Alessandra Vacca, Kamal Solanki, Douglas Veale, Esthela Loyo, Carmen Tineo, Mengtao Li, Edoardo Rosato, Fahrettin Oksel, Figen Yargucu, Cristina-Mihaela Tanaseanu, Rosario Foti, Codrina Ancuta, Britta Maurer, Jacob van Laar, Marzena Olesinska, Cristiane Kayser, Nihal Fathi, Paloma García de la Peña Lefebvre, Jorge Juan Gonzalez Martin, Jean Sibilia, Ira Litinsky, Francesco Del Galdo, Lesley Ann Saketkoo, Eduardo Kerzberg, Washington Bianch, Breno Valdetaro Bianchi, Ivan Castellví, Massimiliano Limonta, Doron Rimar, Maura Couto, François Spertini, Antonella Marcoccia, Sarah Kahl, Ivien M Hsu, Thierry Martin, Sergey Moiseev, Pavel Novikov, Lorinda S Chung, Tim Schmeiser, Dominik Majewski, Zbigniew Zdrojewski, Julia Martínez-Barrio, Vera Bernardino, Gabriela Riemekasten, Yair Levy, Elena Rezus, Omer Nuri Pamuk, Piercarlo Sarzi Puttini, Hadi Poormoghim, Ina Kötter, Francis Gaches, Laura Belloli, Petros Sfikakis, Daniel Furst, Ana-Maria Ramazan, H U Scherer, Tom W J Huizinga, Marie-Elise Truchetet, Alain Lescoat, Giacomo De Luca, Corrado Campochiaro, J M van Laar, Lidia Rudnicka, Susana Oliveira, Fabiola Atzeni, Masataka Kuwana, Arsene Mekinian, Cédric L, Mathieu Puyade, Pascal Roblot, Satoshi Kubo, Yasuyuki Todoroki, 1, Alexandru Garaiman, 2, Klaus Steigmiller, 3, Catherine Gebhard, 1, Carina Mihai, 1, Rucsandra Dobrota, 4, Cosimo Bruni, 5, Marco Matucci-Cerinic, 6, Joerg Hene, 7, Jeska de Vries-Bouwstra, 8, Vanessa Smith, 9, Andrea Doria, Allanore 10, Yannick, Dagna 11, Lorenzo, Anić 12, Branimir, Montecucco 13, Carlomaurizio, Kowal-Bielecka 14, Otylia, Martin 15, Mickael, Tanaka 16, Yoshiya, Hoffmann-Vold 17, Anna-Maria, 2, Ulrike Held, 1, Oliver Distler, 1, Mike Oliver Becker, Silvia Bellando Randone, Eustar, Lepri, Gemma, Walker, Ulrich, Iannone, Florenzo, Jordan, Suzana, Becvar, Radim, Gindzienska-Sieskiewicz, Ewa, Karaszewska, Katarzyna, Cutolo, Maurizio, Cuomo, Giovanna, Siegert, Elise, Rednic, Simona, Avouac, Jérome, Desbas, Carole, Caporali, Roberto, Cavagna, Lorenzo, E Carreira, Patricia, Novak, Srdan, Czirják, László, Iudici, Michele, J Kucharz, Eugene, Zanatta, Elisabetta, Coleiro, Bernard, Moroncini, Gianluca, Farge Bancel, Dominique, Airò, Paolo, Hesselstr, Roger, Radic, Mislav, Balbir-Gurman, Alexandra, Hunzelmann, Nicola, Pellerito, Raffaele, Giollo, Alessandro, Morovic-Vergles, Jadranka, Denton, Christopher, Damjanov, Nemanja, Pecher, Ann-Christian, Ortiz Santamaria, Vera, Heitmann, Stefan, Krasowska, Dorota, Hasler, Paul, Foeldvari, Ivan, João Salvador, Maria, Stamenkovic, Bojana, Francesco Selmi, Carlo, P Ananieva, Lidia, Herrick, Ariane, Müller-Ladner, Ulf, DE PALMA, Raffaele, Engelhart, Merete, Szücs, Gabriela, de la Puente, Carlo, Midtvedt, Øyvind, Garen, Torhild, Fretheim, Håvard, Hachulla, Eric, Riccieri, Valeria, Maria Ionescu, Ruxandra, Maria Gheorghiu, Ana, Sunderkötter, Cord, Distler, Jörg, Ingegnoli, Francesca, Mouthon, Luc, Paolo Cantatore, Francesco, Ullman, Susanne, Rosa Pozzi, Maria, Eyerich, Kilian, Wiland, Piotr, Vanthuyne, Marie, Jose Alegre-Sancho, Juan, Herrmann, Kristine, De Langhe, Ellen, Baresic, Marko, Mayer, Miroslav, Yavuz, Sule, Granel, Brigitte, de Souza Müller, Carolina, Agachi, Svetlana, Stebbings, Simon, Mathieu, D'Alessandro, Vacca, Alessandra, Solanki, Kamal, Veale, Dougla, Loyo, Esthela, Tineo, Carmen, Li, Mengtao, Rosato, Edoardo, Oksel, Fahrettin, Yargucu, Figen, Tanaseanu, Cristina-Mihaela, Foti, Rosario, Ancuta, Codrina, Maurer, Britta, van Laar, Jacob, Olesinska, Marzena, Kayser, Cristiane, Fathi, Nihal, García de la Peña Lefebvre, Paloma, Juan Gonzalez Martin, Jorge, Sibilia, Jean, Litinsky, Ira, Del Galdo, Francesco, Ann Saketkoo, Lesley, Kerzberg, Eduardo, Bianch, Washington, Valdetaro Bianchi, Breno, Castellví, Ivan, Limonta, Massimiliano, Rimar, Doron, Couto, Maura, Spertini, Françoi, Marcoccia, Antonella, Kahl, Sarah, M Hsu, Ivien, Martin, Thierry, Moiseev, Sergey, Novikov, Pavel, S Chung, Lorinda, Schmeiser, Tim, Majewski, Dominik, Zdrojewski, Zbigniew, Martínez-Barrio, Julia, Bernardino, Vera, Riemekasten, Gabriela, Levy, Yair, Rezus, Elena, Nuri Pamuk, Omer, Sarzi Puttini, Piercarlo, Poormoghim, Hadi, Kötter, Ina, Gaches, Franci, Belloli, Laura, Sfikakis, Petro, Furst, Daniel, Ramazan, Ana-Maria, U Scherer, H, J Huizinga, Tom W, Truchetet, Marie-Elise, Lescoat, Alain, De Luca, Giacomo, Campochiaro, Corrado, M van Laar, J, Rudnicka, Lidia, Oliveira, Susana, Atzeni, Fabiola, Kuwana, Masataka, Mekinian, Arsene, L, Cédric, Puyade, Mathieu, Roblot, Pascal, Kubo, Satoshi, Todoroki, Yasuyuki, and University of Zurich
- Subjects
prognostic prediction model ,Rheumatology ,10051 Rheumatology Clinic and Institute of Physical Medicine ,digital ulcers ,platelets inhibitors ,610 Medicine & health ,Pharmacology (medical) ,SSc ,10060 Epidemiology, Biostatistics and Prevention Institute (EBPI) - Abstract
Objective To develop and validate the prognostic prediction model DU-VASC to assist the clinicians in decision-making regarding the use of platelet inhibitors (PIs) for the management of digital ulcers in patients with systemic sclerosis. Secondly, to assess the incremental value of PIs as predictor. Methods We analysed patient data from the European Scleroderma Trials and Research group registry (one time point assessed). Three sets of derivation/validation cohorts were obtained from the original cohort. Using logistic regression, we developed a model for prediction of digital ulcers (DUs). C-Statistics and calibration plots were calculated to evaluate the prediction performance. Variable importance plots and the decrease in C-statistics were used to address the importance of the predictors. Results Of 3710 patients in the original cohort, 487 had DUs and 90 were exposed to PIs. For the DU-VASC model, which includes 27 predictors, we observed good calibration and discrimination in all cohorts (C-statistic = 81.1% [95% CI: 78.9%, 83.4%] for the derivation and 82.3% [95% CI: 779.3%, 85.3%] for the independent temporal validation cohort). Exposure to PIs was associated with absence of DUs and was the most important therapeutic predictor. Further important factors associated with absence of DUs were lower modified Rodnan skin score, anti-Scl-70 negativity and normal CRP. Conversely, the exposure to phosphodiesterase-5 inhibitor, prostacyclin analogues or endothelin receptor antagonists seemed to be associated with the occurrence of DUs. Nonetheless, previous DUs remains the most impactful predictor of DUs. Conclusion The DU-VASC model, with good calibration and discrimination ability, revealed that PI treatment was the most important therapy-related predictor associated with reduced DU occurrence.
- Published
- 2022
44. Update of EULAR recommendations for the treatment of systemic sclerosis
- Author
-
Kowal-Bielecka O., Fransen J., Avouac J., Becker M., Kulak A., Allanore Y., Distler O., Clements P., Cutolo M., Czirjak L., Damjanov N., Del Galdo F., Denton C. P., Distler J. H. W., Foeldvari I., Figelstone K., Frerix M., Furst D. E., Guiducci S., Hunzelmann N., Khanna D., Matucci-Cerinic M., Herrick A. L., Van Den Hoogen F., Van Laar J. M., Riemekasten G., Silver R., Smith V., Sulli A., Tarner I., Tyndall A., Welling J., Wigley F., Valentini G., Walker U. A., Zulian F., Muller-Ladner U., Daikeler T., Lanciano E., Becvar R., Tomcik M., Gindzienska-Sieskiewicz E., Cuomo G., Iudici M., Rednic S., Vlachoyiannopoulos P. G., Caporali R., Carreira P. E., Novak S., Minier T., Kucharz E. J., Gabrielli A., Moroncini G., Airo' P., Hesselstrand R., Martinovic D., Radic M., Marasovic-Krstulovic D., Braun-Moscovici Y., Balbir-Gurman A., Lo Monaco A., Caramaschi P., Morovic-Vergles J., Henes J., Ortiz Santamaria V., Heitmann S., Krasowska D., Seidel M. F., Hasler P., Pereira Da Silva J. A., Salvador M. J., Stamenkovic B., Stankovic A., Tikly M., Ananieva L. P., Beretta L., Szucs G., Szamosi S., de la Puente Bujidos C., Midtvedt O., Hoffmann-Vold A. -M., Launay D., Hachulla E., Riccieri V., Ionescu R., Opris D., Mihai C., Herrgott I., Beyer C., Ingegnoli F., von Muhlen C. A., Alegre-Sancho J. J., Beltran-Catalan E., Aringer M., Fantana J., Leuchten N., Tausche A. -K., De Langhe E., Vanthuyne M., Anic B., Baresic M., Mayer M., Uprus M., Otsa K., Yavuz S., Granel B., Azevedo V. F., Muller C., Jimenez S. A., Popa S., Agachi S., Zenone T., Stebbings S., Dockerty J., Vacca A., Schollum J., Veale D. J., Toloza S., Xu D., Olas J., Rosato E., Foti R., Adler S., Dan D., Wiesik-Szewczyk E., Olesinska M., Kayser C., Fathi N., de la Pena Lefebvre P. G., Imbert B., Kowal-Bielecka, O., Fransen, J., Avouac, J., Becker, M., Kulak, A., Allanore, Y., Distler, O., Clements, P., Cutolo, M., Czirjak, L., Damjanov, N., Del Galdo, F., Denton, C. P., Distler, J. H. W., Foeldvari, I., Figelstone, K., Frerix, M., Furst, D. E., Guiducci, S., Hunzelmann, N., Khanna, D., Matucci-Cerinic, M., Herrick, A. L., Van Den Hoogen, F., Van Laar, J. M., Riemekasten, G., Silver, R., Smith, V., Sulli, A., Tarner, I., Tyndall, A., Welling, J., Wigley, F., Valentini, G., Walker, U. A., Zulian, F., Muller-Ladner, U., Daikeler, T., Lanciano, E., Becvar, R., Tomcik, M., Gindzienska-Sieskiewicz, E., Cuomo, G., Iudici, M., Rednic, S., Vlachoyiannopoulos, P. G., Caporali, R., Carreira, P. E., Novak, S., Minier, T., Kucharz, E. J., Gabrielli, A., Moroncini, G., Airo', P., Hesselstrand, R., Martinovic, D., Radic, M., Marasovic-Krstulovic, D., Braun-Moscovici, Y., Balbir-Gurman, A., Lo Monaco, A., Caramaschi, P., Morovic-Vergles, J., Henes, J., Ortiz Santamaria, V., Heitmann, S., Krasowska, D., Seidel, M. F., Hasler, P., Pereira Da Silva, J. A., Salvador, M. J., Stamenkovic, B., Stankovic, A., Tikly, M., Ananieva, L. P., Beretta, L., Szucs, G., Szamosi, S., de la Puente Bujidos, C., Midtvedt, O., Hoffmann-Vold, A. -M., Launay, D., Hachulla, E., Riccieri, V., Ionescu, R., Opris, D., Mihai, C., Herrgott, I., Beyer, C., Ingegnoli, F., von Muhlen, C. A., Alegre-Sancho, J. J., Beltran-Catalan, E., Aringer, M., Fantana, J., Leuchten, N., Tausche, A. -K., De Langhe, E., Vanthuyne, M., Anic, B., Baresic, M., Mayer, M., Uprus, M., Otsa, K., Yavuz, S., Granel, B., Azevedo, V. F., Muller, C., Jimenez, S. A., Popa, S., Agachi, S., Zenone, T., Stebbings, S., Dockerty, J., Vacca, A., Schollum, J., Veale, D. J., Toloza, S., Xu, D., Olas, J., Rosato, E., Foti, R., Adler, S., Dan, D., Wiesik-Szewczyk, E., Olesinska, M., Kayser, C., Fathi, N., de la Pena Lefebvre, P. G., Imbert, B., UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (MGD) Service de rhumatologie, Kowal Bielecka, Otylia, Fransen, Jaap, Avouac, Jerome, Becker, Mike, Kulak, Agnieszka, Allanore, Yannick, Distler, Oliver, Clements, Philip, Cutolo, Maurizio, Czirjak, Laszlo, Damjanov, Nemanja, del Galdo, Francesco, Denton, Christopher P., Distler, Jörg H. W., Foeldvari, Ivan, Figelstone, Kim, Frerix, Marc, Furst, Daniel E., Guiducci, Serena, Hunzelmann, Nicola, Khanna, Dinesh, Matucci Cerinic, Marco, Herrick, Ariane L., van den Hoogen, Frank, van Laar, Jacob M., Riemekasten, Gabriela, Silver, Richard, Smith, Vanessa, Sulli, Alberto, Tarner, Ingo, Tyndall, Alan, Welling, Joep, Wigley, Frederic, Valentini, Gabriele, Walker, Ulrich A., Zulian, Francesco, Müller Ladner, Ulf, Daikeler, Thoma, Lanciano, Elisabetta, Becvã¡r, Radim, Tomcik, Michal, Gindzienska Sieskiewicz, Ewa, Iudici, Michele, Rednic, Simona, Vlachoyiannopoulos, Panayiotis G., Caporali, Roberto, Carreira, Patricia E., Novak, Srdan, Minier, Tã¼nde, Kucharz, Eugene J., Gabrielli, Armando, Moroncini, Gianluca, Airo, Paolo, Hesselstrand, Roger, Martinovic, Duska, Radic, Mislav, Marasovic Krstulovic, Daniela, Braun Moscovici, Yolanda, Monaco, Andrea Lo, Morovic Vergles, Jadranka, Culo, Melanie I., Henes, Jã¶rg, Santamaria, Vera Ortiz, Heitmann, Stefan, Krasowska, Dorota, Michalska Jakubus, Malgorzata, Seidel, Matthias F., Klinik III, Medizinische, Hasler, Paul, Da Silva, José A. Pereira, Salvador, Maria J., Stamenkovic, Bojana, Stankovic, Aleksandra, Tikly, Mohammed, Ananieva, Lidia P., Beretta, Lorenzo, Szucs, Gabriella, Szamosi, Szilvia, de la Puente Bujidos, Carlo, Midtvedt, Øyvind, Hoffmann Vold, Anna Maria, Launay, David, Hachulla, Eric, Riccieri, Valeria, Ionescu, Ruxandra, Opris, Daniela, Mihai, Carina, Herrgott, Ilka, Beyer, Christian, Ingegnoli, Francesca, von Mühlen, Carlos Alberto, Alegre Sancho, Juan José, Beltran Catalan, Emma, Aringer, Martin, Fantana, Julia, Leuchten, Nicolai, Tausche, Anne Kathrin, Langhe, Ellen De, Vanthuyne, Marie, Anic, Branimir, Bareå¡ic, Marko, Mayer, Miroslav, Ãœprus, Maria, Otsa, Kati, Yavuz, Sule, Granel, Brigitte, Jimenez, Sergio A., Popa, Serghei, Agachi, Svetlana, Zenone, Thierry, Stebbings, Simon, Dockerty, Joanne, Vacca, Alessandra, Schollum, Joanna, Veale, Douglas J., Toloza, Sergio, Xu, Dong, Olas, Jacek, Rosato, Edoardo, Foti, Rosario, Adler, Sabine, Dan, Diana, Wiesik Szewczyk, Ewa, Olesinska, Marzena, Kayser, Cristiane, Fathi, Nihal, de la Peña Lefebvre, Paloma GarcÃa, Imbert, Bernard, and Cuomo, Giovanna
- Subjects
Endothelin Receptor Antagonists ,Lung Diseases ,Kidney Disease ,Delphi Technique ,Gastrointestinal Diseases ,systemic sclerosis ,Scleroderma Renal Crisis ,Placebo-controlled study ,Angiotensin-Converting Enzyme Inhibitors ,Lung Disease ,Scleroderma ,0302 clinical medicine ,Glucocorticoid ,Phosphodiesterase 5 Inhibitor ,Immunology and Allergy ,skin and connective tissue diseases ,BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina ,integumentary system ,treatment ,genetics and molecular biology (all) ,Hematopoietic Stem Cell Transplantation ,cyclophosphamide ,methotrexate ,Pulmonary ,Orvostudományok ,Serotonin Uptake Inhibitor ,3. Good health ,Europe ,Systematic review ,Hypertension ,Serotonin Uptake Inhibitors ,Cyclophosphamide ,Methotrexate ,Systemic Sclerosis ,Treatment ,Fingers ,Fluoxetine ,Glucocorticoids ,Humans ,Hypertension, Pulmonary ,Kidney Diseases ,Phosphodiesterase 5 Inhibitors ,Prostaglandins I ,Pyrazoles ,Pyrimidines ,Raynaud Disease ,Rheumatology ,Scleroderma, Systemic ,Ulcer ,Immunology ,Biochemistry, Genetics and Molecular Biology (all) ,030211 gastroenterology & hepatology ,Endothelin Receptor Antagonist ,Selective Serotonin Reuptake Inhibitors ,medicine.drug ,Human ,medicine.medical_specialty ,Gastrointestinal Disease ,Klinikai orvostudományok ,Riociguat ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,medicine ,Finger ,biochemistry ,Intensive care medicine ,BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine ,Systemic Sclerosi ,030203 arthritis & rheumatology ,business.industry ,Systemic ,Angiotensin-Converting Enzyme Inhibitor ,medicine.disease ,Transplantation ,Clinical research ,Pyrimidine ,immunology and allergy ,rheumatology ,immunology ,Pyrazole ,Physical therapy ,business ,Rheumatism - Abstract
The aim was to update the 2009 European League against Rheumatism (EULAR) recommendations for the treatment of systemic sclerosis (SSc), with attention to new therapeutic questions. Update of the previous treatment recommendations was performed according to EULAR standard operating procedures. The task force consisted of 32 SSc clinical experts from Europe and the USA, 2 patients nominated by the pan-European patient association for SSc (Federation of European Scleroderma Associations (FESCA)), a clinical epidemiologist and 2 research fellows. All centres from the EULAR Scleroderma Trials and Research group were invited to submit and select clinical questions concerning SSc treatment using a Delphi approach. Accordingly, 46 clinical questions addressing 26 different interventions were selected for systematic literature review. The new recommendations were based on the available evidence and developed in a consensus meeting with clinical experts and patients. The procedure resulted in 16 recommendations being developed (instead of 14 in 2009) that address treatment of several SSc-related organ complications: Raynaud's phenomenon (RP), digital ulcers (DUs), pulmonary arterial hypertension (PAH), skin and lung disease, scleroderma renal crisis and gastrointestinal involvement. Compared with the 2009 recommendations, the 2016 recommendations include phosphodiesterase type 5 (PDE-5) inhibitors for the treatment of SSc-related RP and DUs, riociguat, new aspects for endothelin receptor antagonists, prostacyclin analogues and PDE-5 inhibitors for SSc-related PAH. New recommendations regarding the use of fluoxetine for SSc-related RP and haematopoietic stem cell transplantation for selected patients with rapidly progressive SSc were also added. In addition, several comments regarding other treatments addressed in clinical questions and suggestions for the SSc research agenda were formulated. These updated data-derived and consensus-derived recommendations will help rheumatologists to manage patients with SSc in an evidence-based way. These recommendations also give directions for future clinical research in SSc.
- Published
- 2017
45. IL-1β, IL-10 and TNF-α polymorphisms may affect systemic lupus erythematosus risk and phenotype.
- Author
-
Rzeszotarska E, Sowinska A, Stypinska B, Lutkowska A, Felis-Giemza A, Olesinska M, Puszczewicz M, Majewski D, Jagodzinski PP, Haładyj E, and Paradowska-Gorycka A
- Subjects
- Cytokines, Genotype, Humans, Phenotype, Polymorphism, Genetic, Interleukin-10 blood, Interleukin-10 genetics, Interleukin-1beta blood, Interleukin-1beta genetics, Lupus Erythematosus, Systemic blood, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic genetics, Tumor Necrosis Factor-alpha blood, Tumor Necrosis Factor-alpha genetics
- Abstract
Objectives: Systemic lupus erythematosus (SLE) is an autoimmune disease, and IL-1β, IL-10, and TNF-α genes are important in the pathogenesis of this disease. We studied the impact of IL-1β-511, IL-1β +3953, IL-10 -592, IL-10 -1082, TNF-α -308, TNF-α -238, and TNF-α +489 polymorphisms on SLE risk and phenotype in SLE patients and healthy controls., Methods: We genotyped SLE patients and healthy controls by real-time PCR on QuantStudio 5 (Applied Biosystems) and measured levels of cytokines by enzyme-linked immunosorbent assay (ELISA)., Results: We indicated that TNF-α -308, IL-10 -592, IL-10 -1082, IL-1β-511 and IL-1β +3953 polymorphisms affect SLE risk. Furthermore, we exposed that some of the TNF-α +489, TNF-α -238, IL-10 -1082 and IL-1β +3953 genotypes are connected with the SLE phenotype. Moreover, we discovered the linking between specific genotypes and the serum concentrations of TNF-α, IL-1β, and IL-10., Conclusions: In conclusion, our study revealed that IL-1β-511, IL-1β +3953, IL-10 -592, IL-10 -1082, and TNF-α -308 polymorphisms may affect SLE risk and phenotype.
- Published
- 2022
- Full Text
- View/download PDF
46. IL-6 and TGF-β gene polymorphisms, their serum levels, as well as HLA profile, in patients with systemic lupus erythematosus.
- Author
-
Paradowska-Gorycka A, Roszak M, Stypinska B, Lutkowska A, Walczyk M, Olesinska M, Wajda A, Piotrowski P, Puszczewicz M, Majewski D, and Jagodzinski PP
- Subjects
- Alleles, Case-Control Studies, Gene Frequency, Genetic Predisposition to Disease, Genotype, HLA-DRB1 Chains, Humans, Poland, Interleukin-6 blood, Interleukin-6 genetics, Lupus Erythematosus, Systemic genetics, Polymorphism, Genetic, Transforming Growth Factor beta blood, Transforming Growth Factor beta genetics
- Abstract
Objectives: The aim of the study was to explore whether TGF-β and IL-6 gene polymorphisms may be associated with SLE and assess the frequency of HLA-DRB1 alleles in Polish systemic lupus erythematosus (SLE) patients., Methods: 216 SLE patients and 552 healthy individuals were examined for TGF-β rs1800469 and rs1800470 by TaqMan SNP genotyping assay and for and IL-6(rs2069827 and rs1800795 using the PCR- RFLP method., Results: An increased frequency of TT genotype and T allele of the TGF β -509 C/T was found in SLE patients (p=0.02). The TGF-β 869 C allele was more frequent in SLE patients. The genotype-phenotype analysis showed association between the TGF β -509 C/T and mean value of CRP, ESR, haemoglobin, APTT, Pt and INR (p=0.05, p=0.03, p<0.001, p=0.03, p=0.03 and p=0.05, respectively) as well as anti-SSA and anti-Sm presence (p=0.04 and p=0.03, respectively); the TGF- β 869 T/C and mean value of APTT and INR (p=0.01 and p=0.05, respectively); the IL-6 -174 G/C and SLICC (p=0.05), anti-SSA (p=0.05) and anti-SSB (p=0.05). A higher TGF-β and IL-6 serum level were found in SLE patients compared to controls (both p<0.0001). In SLE patients with the TGF-β -509 TT genotype have shown positive association with the TGF-β serum levels. Polish SLE patients have strong positive association with HLA-DRB1*52.1, and negative with the HLA-DRB1*07:01 allele. HLA-DRB1*52.1 was also associated with higher TGF-β serum levels in the Polish population., Conclusions: Our results suggested that the TGF β -509 C/T variant may be considered as a genetic marker for SLE in the Polish population.
- Published
- 2019
47. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups.
- Author
-
Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dankó K, Dimachkie MM, Feldman BM, Garcia-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, and Rider LG
- Subjects
- Adolescent, Adult, Biopsy standards, Child, Consensus, Europe, Female, Humans, Male, Middle Aged, Muscle, Skeletal pathology, Sensitivity and Specificity, Societies, Medical, Symptom Assessment methods, United States, Young Adult, Myositis classification, Myositis diagnosis, Practice Guidelines as Topic, Rheumatology standards, Symptom Assessment standards
- Abstract
Objective: To develop and validate new classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIM) and their major subgroups., Methods: Candidate variables were assembled from published criteria and expert opinion using consensus methodology. Data were collected from 47 rheumatology, dermatology, neurology, and pediatric clinics worldwide. Several statistical methods were utilized to derive the classification criteria., Results: Based on data from 976 IIM patients (74% adults; 26% children) and 624 non-IIM patients with mimicking conditions (82% adults; 18% children), new criteria were derived. Each item is assigned a weighted score. The total score corresponds to a probability of having IIM. Subclassification is performed using a classification tree. A probability cutoff of 55%, corresponding to a score of 5.5 (6.7 with muscle biopsy) "probable IIM," had best sensitivity/specificity (87%/82% without biopsies, 93%/88% with biopsies) and is recommended as a minimum to classify a patient as having IIM. A probability of ≥90%, corresponding to a score of ≥7.5 (≥8.7 with muscle biopsy), corresponds to "definite IIM." A probability of <50%, corresponding to a score of <5.3 (<6.5 with muscle biopsy), rules out IIM, leaving a probability of ≥50-<55% as "possible IIM.", Conclusion: The European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for IIM have been endorsed by international rheumatology, dermatology, neurology, and pediatric groups. They employ easily accessible and operationally defined elements, and have been partially validated. They allow classification of "definite," "probable," and "possible" IIM, in addition to the major subgroups of IIM, including juvenile IIM. They generally perform better than existing criteria., (© 2017, American College of Rheumatology.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.